NCT06154902

Real-World Outcomes in Relapsed/Refractory Multiple Myeloma Patients Treated, or Eligible for Treatment, With Idecabtagene Vicleucel

ABE-DESCART Study: Characterization and Outcomes of Patients With Relapsed and Refractory Multiple Myeloma Eligible for Treatment or Treated With Abecma© (Idecabtagene Vicleucel) in Real World Setting in France. A Database Analysis Based on the DESCAR-T Registry

• Status: Active Not Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 350 (estimated)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to describe demographic and disease characteristics, treatment patterns, and clinical outcomes in the real-world setting among participants in France with relapsed/refractory multiple myeloma (RRMM) who are eligible for treatment with, or have been treated with, idecabtagene vicleucel. This study will use both prospective and retrospective data from the DESCAR-T registry database.

Conditions

• Multiple Myeloma

Interventions

Type	Name	Description
DRUG	Idecabtagene vicleucel	According to approved product label in France
OTHER	Not treated	Eligible for idecabtagene vicleucel treatment but not treated

Timeline

• Start date: 2022-07-29
• Primary completion: 2027-07-31
• Completion: 2027-12-31
• First posted: 2023-12-04
• Last updated: 2023-12-04

Locations

1 site across 1 country: France

Regulatory

• FDA-regulated drug study